Investigation of circRNA-miRNA-mRNA network in colorectal cancer using an integrative bioinformatics approach

Sepideh Kadkhoda1*, Farzaneh Darbeheshti2*, Nima Rezaei3,4,5, Ghasem Azizì-Tabesh6,7, Faezeh Zolfaghari1, Sadollah Tavakolibazaz8, Reza Taslimi9, Javad Tavakkoly-Bazzaz1

1 Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 Breast Cancer Association (BcCA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
3 Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
6 Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8 Department of Gastrointestinal Dis., Imam Reza Hospital, Mazandaran University of Medical Sciences, Amol, Iran
9 Department of Gastroenterology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
1*Sepideh Kadkhoda and Farzaneh Darbeheshti contributed equally to this study as first authors

ABSTRACT

Aim: The aim of this study was to integrate both coding and non-coding available microarray data in the development of colorectal cancer (CRC) with bioinformatics analyses to attain a more inclusive pathobiologic map of their molecular interactions and functions.

Background: Identification of competing endogenous RNAs (ceRNAs), especially circRNAs, has become a new hotspot in cancer research, although their roles and underlying mechanisms in CRC development remain mostly unknown.

Methods: Microarray data was retrieved from the Gene Expression Omnibus (GEO) database and analyzed. Several bioinformatics tools and databases were applied for further elucidation. Principal component analysis (PCA) was run separately for four datasets. The dysregulated circRNA-miRNA-mRNA co-expression, and protein-protein interaction (PPI) networks were established.

Results: PCA discloses colorectal tumors; normal tissue can be distinguished not only by mRNAs expression profile, but also by both circRNA and miRNA expression profiles. In this study, 14 DE mRNAs, 85 DE miRNAs, and 36 DE circRNAs were identified in CRC tissue and compared with normal tissue. Taking their potential interactions into account, a circRNA-miRNA-mRNA network was constructed. The results disclosed some DE circRNAs with potential oncogenic (circ_0014879) or tumor suppressive (circ_0001666 and circ_0000977) effects. Finally, the PPI network suggests pivotal roles for DOCK2 and PTPRC dysregulation in the progression of CRC, possibly by facilitating tumor escape from immune surveillance.

Conclusion: The current study proposes a novel regulatory network consisting of DE circRNAs, miRNAs, and mRNAs in CRC development that highlights the roles of DE circRNAs at the upstream of oncotranscriptomic cascade in CRC development, suggesting their potential to be utilized as both prognostic and therapeutic biomarkers.

Keywords: circRNA, miRNA, Colorectal cancer, Microarray, Bioinformatics.

(Please cite as: Kadkhoda S, Darbeheshti F, Rezaei N, Azizi-Tabesh GH, Zolfaghari F, Tavakolibazaz S, et al. Investigation of circRNA-miRNA-mRNA network in colorectal cancer using an integrative bioinformatics approach. Gastroenterol Hepatol Bed Bench 2021;14(2):141-153).

Introduction

Colorectal cancer (CRC) was classified as the third most prevalent and second most lethal malignancy in

Accepted: 29 August 2020
Reprint or Correspondence: Nima Rezaei MD, PhD& Javad Tavakkoly-Bazzaz MD, PhD Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran & Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
E-mail: rezaei_nima@tums.ac.ir, tavakkolybazzazj@tums.ac.ir
ORCID ID: 0000-0001-5951-1049

©2021 RIGLD, Research Institute for Gastroenterology and Liver Diseases
be well treated and managed with suitable and early diagnosis. Thus, a better understanding of molecular signatures, potential biomarkers, and therapeutic targets in CRC is necessary to gradually improve the diagnosis and treatment efficacy.

Today, high throughput technologies have aided the discovery and investigation of both coding and non-coding dysregulated transcripts in tumor cells. The pivotal roles of non-coding RNAs in gene expression regulation and, consequently, cancer initiation and progression have been determined. Recently, circular RNAs (circRNAs), as a newfound category of non-coding RNAs, were highlighted in cancer research. In relevant studies, circRNAs showed the potential to be diagnostic and prognostic biomarkers due to their high stability and tissue/stage specificity (2). In 2011, the competing endogenous RNA (ceRNA) hypothesis was proposed by Salmena et al. (3), who demonstrated that RNA transcripts communicate with each other through microRNA response elements (MREs). According to this hypothesis, the role of circRNA as a microRNA sponge and the consequent dysregulation of protein-coding gene expression have been established in different malignancies (4, 5). Although various circRNAs have been reported to participate in the pathogenesis of CRC, their molecular interactions with other transcripts are still unknown (6). These interactions could improve current knowledge about the underlying molecular mechanisms and potential targeted therapies in CRC. Integrating experimental data with bioinformatics could present a powerful method to disclose molecular interactions among different transcripts in tumor cells as well as their potential functions.

The aim of this study was to integrate available microarray data concerning circRNAs, miRNAs, and mRNAs in CRC with bioinformatic analyses by consensus strategy to gain a more accurate comprehension of their molecular interactions and functions. A dysregulated circRNA-miRNA-mRNA network was constructed in colorectal tumors as well as co-expression and protein-protein interaction (PPI) networks. The findings propose a novel regulatory network underlying CRC progression and uncover molecular interactions between dysregulated transcripts in colorectal tumors.

**Table 1.** Characteristics of four colorectal cancer-related GEO microarray datasets; T: tumor; N: normal

| GEO         | Platform | Year | Country | Sample size |
|-------------|----------|------|---------|-------------|
| GSE41657    | GPL6480  | 2015 | China   | 10 T/10 N   |
| GSE128449   | GPL4133  | 2019 | Spain   | 25 T/5 N    |
| GSE128449   | GPL14767 | 2019 | Spain   | 20 T/4 N    |
| GSE126095   | GPL19978 | 2019 | China   | 10 T/10 N   |

**Table 2.** Characteristics of differentially expressed circRNAs in GSE126095 with log fold change ≥3 which are involved in dysregulated circRNA-miRNA-mRNA network (Fig. 4A). The red and black rows show down-expressed and up-expressed circRNAs, respectively.

| circRNA          | Alias              | Log FC | Category | Chromosome | Host gene         |
|------------------|--------------------|--------|----------|------------|-------------------|
| hsa_circRNA_102619 | hsa_circ_0000977   | -5.2   | exonic   | chr2       | NOL10            |
| hsa_circRNA_104270 | hsa_circ_0016666   | -4.2   | exonic   | chr6       | FAM120B          |
| hsa_circRNA_104475 | hsa_circ_0082182   | 3.6    | exonic   | chr7       | FAM71F2          |
| hsa_circRNA_100367 | hsa_circ_0014879   | 3.3    | exonic   | chr1       | DCAF8            |
| hsa_circRNA_104640 | hsa_circ_0001806   | 3.6    | exonic   | chr8       | CSPP1            |
| hsa_circRNA_103188 | hsa_circ_0062682   | 3.4    | exonic   | chr22      | TPST2            |
| hsa_circRNA_103348 | hsa_circ_0065214   | 3.2    | exonic   | chr3       | SCAP             |
| hsa_circRNA_101555 | hsa_circ_0001955   | 4.1    | exonic   | chr15      | CSNK1G1          |
| hsa_circRNA_001846 | hsa_circ_0000520   | 3.3    | intragenic | chr14      | RPHHI            |
| hsa_circRNA_104499 | hsa_circ_0082564   | 3.3    | exonic   | chr7       | CREB3L2          |
| hsa_circRNA_101744 | hsa_circ_0005699   | 3.2    | exonic   | chr16      | C16orf62         |
| hsa_circRNA_100146 | hsa_circ_0011385   | 3.9    | exonic   | chr1       | EIF3I            |
| hsa_circRNA_101145 | hsa_circ_0028198   | 3.4    | exonic   | chr12      | ANAPC7           |
| hsa_circRNA_100053 | hsa_circ_0099110   | 3      | exonic   | chr1       | MFN2             |
| hsa_circRNA_101164 | hsa_circ_0028602   | 3.1    | exonic   | chr12      | RNFT2            |
| hsa_circRNA_102771 | hsa_circ_0055377   | 3.1    | exonic   | chr2       | CTNNA2           |
Methods

Differentially Expressed Genes from GEO

To investigate and integrate differentially expressed (DE) RNAs in colorectal cancer, four microarray datasets, including both coding and non-coding transcripts, were selected from the Gene Expression Omnibus (GEO) database and analyzed between colorectal tumors and non-tumor tissue.

Information about the four used datasets is summarized in Table 1. All raw expression data was normalized and log2-transformed (Supplementary Fig. 1). Limma, a Bioconductor package for the differential analysis of microarray data, was run to determine DE RNAs in each dataset with the following criteria: Two datasets, GSE41657 (platform GPL6480) and GSE128435 (platform GPL4133), were analyzed separately with a fold change ≥|2| and adj.p.value < 0.05 set as the cut-off point for the selection of DE mRNA. For this step, the following two criteria were used to define consensus: 1) A transcript has to be differentially expressed in the both experiments; 2) The change in expression in a transcript has to be in the same direction (up- or downregulation) in both experiments. Concerning the GSE41657 dataset, only adenocarcinoma and normal samples were extracted for analysis. The subseries 128435 is part of superseries GSE128449.

GSE128449 (platform GPL14767), which is part of superseries GSE128449, was analyzed to determine DE miRNAs. In this step, DE miRNAs with a cut-off point of log fold change ≥|3| and adj.p.value < 0.05 were selected for further analysis.

To assess DE circRNA in CRC, GSE126095 (platform GPL19978) was used, and transcripts with a cut-off point of adj.p.value < 0.05 and log fold change ≥|3| were retrieved. The flowchart of data and bioinformatics analyses is presented in Fig. 1. To investigate similarities and dissimilarities between samples, clustered heatmaps for the top 100 DE RNAs in the four datasets were analyzed.

Principal component analysis (PCA)

The PCA plot evaluates differences and similarities among samples and determines whether samples can be grouped. Hence, it can separate normal and tumor tissues based on their gene expression profiles.

Scatterplots of PCA from four microarray data were generated separately using the ggfortify package in R.

Figure 1. Flowchart of data and bioinformatics analyses

circRNA-miRNA-mRNA network

First, the CircInteractome online database (7) was used to bioinformatically find potential miRNAs with a complementary seed region on DE ciRNAs. For each DE circRNA, all predicted miRNAs were obtained. Next, miRNAs that overlapped with predicted and DE miRNAs were gathered. After that, common targets of DE miRNAs with DE mRNAs that were retrieved from both GSE41657 and GSE128435 were assessed. To this end, miRTarBase (8) was used to detect experimentally validated miRNA-mRNA interactions. Also, two databases, TagetScan (9) and miRmap (10), were run for bioinformatics analysis of the predicted miRNA-mRNA interactions. It should be noted that only interactions that are commonly predicted in both databases were selected. Finally, a dysregulated circRNA-miRNA-mRNA network in colorectal cancer was constructed by Cytoscape version 3.6.1. Characteristics of the 16 DE circRNAs that are involved in this network are shown in Table 2.

Then, the axes that showed expression status according to ceRNA hypothesis were extracted. In this
step, it was presumed that circRNAs show opposite expression direction to their downstream miRNAs and same direction to downstream mRNAs in a circRNA-miRNA-mRNA axis. The Cancer-Specific CircRNA (CSCD) database (11) was used to visualize basic structural patterns of the circRNAs involved in the circRNA-miRNA-gene axis.

**Co-expression Network Construction**

The top 40 co-expressed genes in colorectal cancer for each DE mRNA were retrieved from the GEPIA database (12) according to the Cancer Genome Atlas (TCGA) data. The co-expression network was generated by Cytoscape, and hub nodes were identified according to the degree and betweenness centrality. Finally, the hub genes in this network were functionally analyzed by the DAVID database (13).

**Protein-Protein Interaction (PPI) Network Construction**

First, PPIs were identified by the String database (14), and then the PPI network was visualized by Cytoscape. To identify hub nodes, degree and betweenness centrality were considered. Next, MCODE, a Cytoscape app, was run to find the most significant protein module. Then, the Enrichr database (15) was used to understand the biological function of hub genes in the PPI network.

**Oncogenomic and Oncotranscriptomic Analysis**

cBioPortal v.3 (16) was run to identify somatic alterations of hub genes in 526 colorectal tumor samples according to TCGA, PanCancer atlas. In addition, GEPIA was used to assess the expression of hub genes in CRC tissue compared with normal tissue based on TCGA data.

---

**Figure 2.** A: The Volcano plot of significant differentially expressed mRNAs (GSE41657 and GSE128449,GPL4133) with $\geq |2|$ log fold change, circRNAs (GSE126095) and miRNAs (GSE128449,GPL14767) with $\geq |3|$ log fold change in colorectal tumors and normal colorectal tissues. Red and green dots show down and up regulated RNAs, respectively. B: The scatterplot of PCA from the gene expression profiles in tumor and normal colorectal tissues, including two mRNA microarray datasets (GSE41657 and GSE128449,GPL4133), one circRNA microarray dataset (GSE126095), and one miRNA microarray dataset (GSE128449,GPL14767). The blue points represent colorectal tumor cells, whereas the red ones show normal cells. Distribution of information with respect to differential expression between tumor and normal tissues.

**Table 3.** Functional annotation of hub genes in co-expression network by DAVID database

| Hub genes | GO terms |
|-----------|----------|
| GAS7      | Cell cycle arrest, Regulation of transcription, DNA-templated, Nervous system development, Cell differentiation |
| C10ORF54  | Single organismal cell-cell adhesion |
| TSPAN1    | Cell proliferation, Cell migration, Cell surface receptor signaling pathway, Positive regulation of endocytosis, Protein stabilization |
| RELL1     | Plasma membrane, Microtubule cytoskeleton, Integral component of membrane |
Results

Differentially Expressed mRNAs, miRNAs, and circRNAs

To obtain differentially expressed (DE) protein coding genes in CRC, two GEO datasets (GSE 41657 and GSE 128435) were analyzed. In this step, genes with adj.p.value < 0.05 and log fold change ≥ 2 were selected. Subsequently, 14 common DE genes were found in both datasets that showed the same dysregulation direction (Supplementary Table 1). Two of these genes are up-expressed and 12 are down-expressed. Details of the analysis are shown in Fig. 1.

A GEO dataset concerning the expression of miRNAs in CRC (GSE128449) was analyzed. In this step, 85 DE miRNAs with cutoff criteria of adj.p.value < 0.05 and log fold change ≥ 3 were obtained (Supplementary Table 2).

As mentioned, GSE126095 was examined to find DE circRNAs in CRC. Thirty-six DE circRNAs with adj.p.value < 0.05 and log fold change ≥ 3 were obtained (Supplementary Table 3).

Clustered heatmaps for all analyzed datasets are shown in Fig. 3 and Supplementary Figures 2-4. In addition, volcano plots of DE RNAs in the four datasets have been drawn (Fig. 2A).

The gene expression PCA plot provides insight into the association between samples. As shown in Fig. 2B, colorectal tumor and normal tissues could be distinguished not only by mRNA expression profiles, but also by both circRNA and miRNA expression profiles.

Potential DE circRNA-DE miRNA and DE miRNA-mRNA interactions

According to the circInteractome database, 54 DE circRNA-DE miRNA interactions are bioinformatically predicted. Three databases were run to investigate DE gene-DE miRNA interactions. Six experimentally validated interactions by mirTarbase and 50 bioinformatically predicted interactions by TargetScan and miRmap were consistently obtained (Supplementary Table 4).

CircRNA- miRNA- mRNA network

A dysregulated circRNA- miRNA- mRNA network in colorectal cancer was constructed with 16 circRNAs, 14 miRNAs and 11 mRNAs (Fig. 4A). According to the ceRNA hypothesis, the extracted axes, which consist of five circRNAs, four miRNAs, and eight mRNAs, are presented in Fig. 4B. The circRNAs involved in these axes are available in the Cancer-Specific CircRNA (CSCD) database (Fig. 5).

Co-expression network construction

As mentioned, 11 dysregulated genes related to DE miRNAs were detected. Their top 40 co-expressed genes in CRC were used to construct a co-expression network (Fig. 6). In this network, GAS7, C10ORF54, REL1, and TSPAN1 were considered as hub genes because of their higher degree and betweenness centrality. In addition, functional analysis of hub genes indicates their roles in cancer-related processes, such as cell proliferation and migration (Table 3).

Protein-Protein interaction (PPI) network

The PPI network of 11 DE genes and their co-expressed genes was established after unconnected nodes...
were removed based on String output (Fig. 7A). This network shows PTPRC, SPI1, C3AR1, LCP2, and DOCK2 genes as hub nodes. MCODE was run to detect significant modules (Fig. 7B). It should be noted that all hub nodes are involved in the detected module.

Functional annotation according to the Enrichr web server revealed the roles of hub genes in the immune system (Fig. 7C).
Expression analysis for five hub nodes of the PPI network using GEPIA revealed that while all five are down-expressed in tumors compared with normal tissue, only the dysregulation of DOCK2 and PTPRC is statistically significant (Fig. 8A).

Investigation of DOCK2 and PTPRC somatic mutations in colorectal cancer revealed a fairly high frequency (10% and 8%, respectively) of genetic alterations in tumors. As shown in Fig. 8B, the main proportion of these alterations is composed of missense and truncating mutations.
The circRNA-miRNA-mRNA network in colorectal cancer

Figure 7. A: Protein-Protein Interaction (PPI) network. Data were retrieved from String based on 11 differentially expressed (DE) genes and their co-expressed genes in CRC and visualized by Cytoscape. The color of nodes were determined based on betweenness centrality and their size based on degree; darker color and bigger nodes have more betweenness centrality and degree. Also for determining of the edges width, combined score was considered. B: The main module is extracted from PPI by MCODE cytoscape app. C: Functional annotation for the five hub nodes including SPI1, DOCK2, PTPRC, C3AR1, and LCP2. The graphs were achieved from Enrichr and sorted based on combined score. The longer bar and brighter color represent term that is more.

Figure 8. A: Expression analysis of five hub genes of PPI network between tumors and normal samples. The boxplots were retrieved from GEPIA based on TCGA data including expression of DOCK2, PTPRC, C3AR1, SPI1, and LCP2 from left to right, respectively. Tumors and normal samples present in red and gray, respectively. Red star indicates significant difference between tumors and normal tissues (P.value ≤0.01). B: Genetic alterations of DOCK2 and PTPRC in 526 colorectal tumor samples (the two hubgenes with significant difference expression between tumors and normal tissues). Figures were extracted from cBioPortal based on TCGA, PanCancer atlas.
Discussion

Investigation of non-coding RNAs as well as identification of competing endogenous RNAs (ceRNAs) have become new hotspots in cancer research. Among them, circRNAs are more prominent due to their specific characterizations, such as high stability, time- and tissue-specificity. circRNAs can play an important role in gene expression regulation at both transcriptional and posttranscriptional levels (17). Various studies have demonstrated that dysregulated circRNAs are involved in cancer initiation and progression. For example, up-regulation of hsa_circ_0000069 and its role in cell proliferation, migration, and invasion were observed in CRC (18). Recent evidence has disclosed that circRNAs could sponge miRNA and suppress their functions. Nonetheless, few studies have been conducted concerning circRNA molecular interactions in CRC.

miRNAs are a class of small noncoding RNAs which have pivotal roles in regulating gene expression at the posttranscriptional level by suppressing the target mRNA. It is well known that dysregulated miRNAs are involved in several oncopathways and result in cancer development. In this study, 36 DE circRNAs and 85 DE miRNA with log fold change ≥ 3 were identified in CRC tissue compared with non-tumor tissue as well as 14 DE mRNAs, which consistently showed dysregulation in both GSE41657 and GSE128435 GEO datasets. These DE transcripts were integrated using several databases and bioinformatics tools in order to construct a dysregulated circRNA-miRNA-mRNA network in CRC. In addition, mRNA, miRNA, and circRNA datasets were analyzed separately to assess their ability to separate colorectal tumor and normal samples. The results revealed that each of them alone could distinguish between colorectal tumors and normal samples.

According to the ceRNA hypothesis, it was presumed that circRNAs, as miRNA sponges, show opposite expression direction to their downstream miRNAs and same direction to downstream mRNAs in a circRNA-miRNA-mRNA axis, as 11 axes with this expression status were extracted from the circRNA-miRNA-mRNA network, including five circRNAs, four miRNAs, and eight mRNAs. Previous cancer research concerning these transcripts is summarized in Table 4. However, most of these circRNAs and miRNAs have not been previously reported in CRC. It should be noted that six of the seven detected circRNAs are available in the Cancer-Specific CircRNA Database (CSCD), and the location of their microRNA response elements (MRE) are shown in Fig. 4.

The current study established the potential dysregulated circRNA-miRNA-mRNA axes that could play pivotal roles in CRC oncotranscriptomic. The present analyses revealed that circRNAs can show both oncogenic (oncoCirc) and tumor suppressive functions in CRC. For example, circ_0014879, an up-expressed exonic circRNA, could be an oncoCirc through circ_0014879/miR-885-5p/ARG2 axis. miR-885-5p is bioinformatically predicted to be sponged by circ_0014879. Interestingly, miR-885-5p is a tumor suppressor miRNA and down-expressed in different cancers (Table 4) as well as in the current results. ARG2 is an enzyme that plays a part in the immunosuppressive tumor microenvironment and tumorigenesis. ARG2 is predicted to be a miR-885-5p target. This protein shows overexpression and association with poor prognosis in different cancers. In 2019, Youjun Wu et al. demonstrated that expression of ARG2 is significantly higher in CRC samples than in normal tissue (19). In addition, they revealed that the downregulation of ARG2 inhibits the growth of colorectal cancer cells. According to the current investigation, ARG2 is significantly up-expressed in both GSE41657 and GSE128435 datasets with log fold changes of 2.15 and 2.05, respectively. Therefore, it is suggested that overexpression of circ_0014879 as an oncoCirc could result in the upregulation of the ARG2 oncogene through inhibition of the miR-885-5p function in CRC.

On the other hand, circ_0001666, a down-expressed exonic circRNA, could be a tumor suppressive circRNA in CRC through sponging miR-1276 in the circ_0001666/miR-1276/RASSF2 axis. It was revealed that RASSF2 inhibits tumor cell growth, suggesting that it is a tumor-suppressor gene in CRC (20). Moreover, the present results disclose the potential tumor suppressive roles of circ_0000977 in CRC through sponging miR-1208. Interestingly, this miRNA might posttranscriptionally inhibit two tumor suppressor genes, i.e. IL10RA and AKR1B10 in CRC. In 2018, Zadka et al. reported that IL10RA is down-expressed in CRC tissue and shows a negative correlation with clinical stage and
proliferation (21). It was shown that AKR1B10 expression is significantly decreased in CRC samples, and its down-expression correlates with decreased survival and poor prognosis of patients (22). In addition, AKR1B10 knock-down resulted in the inhibition of apoptosis in colorectal cancer cells. It should be noted that the expression of RASSF2, IL10RA and AKR1B10 was down-regulated in both GSE41657 and GSE128435 datasets with a log fold change < -2. Collectively, it can be proposed that under-expression of both circ_0001666 and circ_0000977, as tumor suppressive circRNAs, contributes to the down-regulation of some tumor suppressive genes in CRC, including RASSF2, IL10RA, and AKR1B10. These findings should be validated through further functional studies in the future.

In the next step, we constructed a dysregulated co-expression network in CRC, including 11 DE genes and their co-expressed genes. This network shows GAS7, C10ORF54, TSPAN1, and RELL1 genes are hub nodes and could play important roles in the progression of CRC tumors as far as the expression profile is concerned. Functional annotation based on the DAVID database revealed their roles in cell proliferation, cell-cell adhesion, cell migration, and cell differentiation (Table 3). Consistently, previous studies have demonstrated their dysregulation in CRC. Remarkable down-regulation of GAS7 due to promoter hypermethylation was reported in CRC (23, 24). It is suggested that the downregulation of GAS7 results in high metastatic ability of tumor cells. RELL1 is a family member of tumor necrosis factor receptor (TNFR) that induces apoptosis (25, 26). This study proposed the important role of RELL1 in CRC oncotranscriptome for the first time; according to the current results, RELL1 shows a significant expression correlation with two down-regulated DE genes, namely RAB3B and ACER3, in CRC-related TCGA data. C10ORF54 (VISTA) is a protein-coding gene which codes immunoregulatory receptors. This protein inhibits the T-cell response and acts during adaptive immune responses (27). Its expression can be a predictive biomarker as far as cancer immunotherapies are concerned (28). Interestingly, the analyses of the current study based on TCGA data (Supplementary Fig. 5) showed that GAS7 and C10ORF54 are significantly downregulated in CRC tissue. However, in 2018, Shan Xie et al. reported that C10ORF54 expression was significantly high in CRC tissue compared with normal tissue (29). It seems that this controversy should be noted in CRC patients who are supposed to receive immunotherapies. Another hub gene in the co-expression network is TSPAN1 which functions in cell mitosis and differentiation. TCGA data showed the significant up-expression of TSPAN1 in CRC tumor compared with normal tissue (Supplementary Fig. 5). It has been reported that overexpression of TSPAN1 is correlated with poor prognostic factors in CRC patients (30). In 2010, Chen et al. reported that the suppression of TSPAN1 results in reduced proliferation and invasion of colon cancer cells (31).

To assess the protein interactions between DE mRNAs and their co-expressed genes, the current study established a PPI network using the STRING search tool. This network revealed two hub nodes, DOCK2 and PTPRC, which significantly downregulate in CRC tumors according to TCGA data (Fig. 7A). Oncogenic analysis showed that a notable proportion of their downregulation is probably attributable to truncating mutations (Fig. 7B), although it seems that transcriptional and post-translational regulatory mechanisms are involved in the downregulation of DOCK2 and PTPRC2 in CRC. Hematopoietic cells express DOCK2 which modulates the activation and migration of immune cells. DOCK2 has been shown to be involved in inflammatory diseases such as malignancies (32). Yu et al. demonstrated that DOCK2 mutation has a high frequency (7.7%) in colon tumors, and low expression of DOCK2 is associated with poor prognoses for patients (33). Another investigation has documented that DOCK2 is a prominent hypermethylated gene in CRC tissue (34). The PTPRC protein is necessary for T-cell activation, and its mutation is associated with severe combined immunodeficiency. Down-regulation of PTPRC has been reported in several cancer types (35, 36). The current study showed that DOCK2 and PTPRC are not only hub nodes of dysregulated PPI in CRC based on degree and betweenness centrality, but are also involved in the module identified with the MCODE algorithm (Fig. 6B). Functional enrichment analysis of module members indicated their roles in the immune system (Fig. 6C). Taken together, it is suggested that the downregulation of DOCK2 and PTPRC in CRC contributes to the escape of tumors.
from immune surveillance; accordingly, their dysregulation could be involved in resistance to immunotherapy.

In conclusion, this study applied the combination of both coding and non-coding microarray data as well as bioinformatics tools to construct the dysregulated circRNA-miRNA-mRNA network and detect ceRNA axes in CRC. Potential oncoCirc (circ_0014879) and tumor suppressive circRNAs (circ_0001666 and circ_0000977) in CRC were identified that could become both prognostic and therapeutic biomarkers. In addition, the PPI network implies the pivotal roles of immune system-related proteins such as DOCK2 and PTPRC in CRC progression, which could be important in immunotherapies.

**Acknowledgment**

The authors would like to acknowledge the GEO, GEPIA, STRING, DIANA, Enrichr, circInteractome, DAVID, eBioportal, CSDC, TargetScan, miRmap and miRTarBase databases as well as Cytoscape software for their free use.

**Conflict of interests**

The authors declare that they have no conflict of interest.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

2. Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in cancer. Cell 2019;176:869-81.

3. Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden language? Cell 2011;146:353-8.

4. Guan YJ, Ma JY, Song W. Identification of circRNA–miRNA–mRNA regulatory network in gastric cancer by analysis of microarray data. Cancer Cell Int 2019;19:183.

5. Sun X, Ge X, Xu Z, Chen D. Identification of circular RNA–microRNA–messenger RNA regulatory network in hepatocellular carcinoma by integrated analysis. Gastroenterol Hepatol 2020;35:157-64.

6. Xu H, Wang C, Song H, Xu Y, Ji G. RNA-Seq profiling of circular RNAs in human colorectal Cancer liver metastasis and the potential biomarkers. Mol Cancer 2019;18:8.

7. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and miRNAs. RNA Biol 2016;13:34-42.

8. Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 2015;44:239-47.

9. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98.

10. Vejnar CE, Blum M, Zdobnov EM. miRmap web: comprehensive microRNA target prediction online. Nucleic Acids Res 2013;41:165-8.

11. Xia S, Feng J, Chen K, Ma Y, Gong J, Cai F, et al. CSDC: a database for cancer-specific circular RNAs. Nucleic Acids Res 2017;46:925-9.

12. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017;45:98-102.

13. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007;35:169-75.

14. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res 2017;45:362-8.

15. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 2016;44:90-7.

16. Gao J, Lindsay J, Watt S, Bahceci I, Lukasse P, Abeshouse A, et al. The eBioportal for cancer genomics and its application in precision oncology. Cancer Res 2016;76:5277.

17. Chen S, Zhao Y. Circular RNAs: Characteristics, function, and role in human cancer. Histol Histopathol 2018;33:887-93.

18. Guo JN, Li J, Zhu CL, Feng WT, Shao JX, Wan L, et al. Comprehensive profile of differentially expressed circular RNAs reveals that hsa_circ_0000069 is upregulated and promotes cell proliferation, migration, and invasion in colorectal cancer. Onco Targets Ther 2016;9:7451.

19. Wu Y, He C, Hu S, Hu Z, Li Y, Xing X, et al. Downregulation of ARG2 inhibits growth of colorectal cancer cells and increases expression of the CD3ζ chain in co-cultured T-cells. Int J Clin Exp Med 2019;12:6946-57.

20. Akino K, Toyota M, Suzuki H, Mita H, Sasaki Y, Ohe-Toyota M, et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 2005;129:156-69.

21. Zadka L, Kulus MJ, Kumor K, Piotrowska A, Glaztel-Plucińska N, Jurek T, et al. The expression of IL10RA in colorectal cancer and its correlation with the proliferation index and the clinical stage of the disease. Cytokine 2018;110:116-25.
The circRNA-miRNA-mRNA network in colorectal cancer

22. Ohashi T, Idogawa M, Sasaki Y, Suzuki H, Tokino T. AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis. Mol Cancer Res 2013;11:1554-63.

23. D’Arrigo A, Belluco C, Ambrosi A, Digito M, Esposito G, Bertola A, et al. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer 2005;115:256-62.

24. Ashktorab H, Darenipouran M, Goel A, Varma S, Leavitt R, Sun X, et al. DNA methylene profiling identifies novel methylated genes in African American patients with colorectal neoplasia. Epigenetics 2014;9:503-12.

25. Cusick JK, Mustian A, Goldberg K, Reylland ME. RELT induces cellular death in HEK 293 epithelial cells. Cell Immunol 2010;261:1-8.

26. Moua P, Checketts M, Xu LG, Shu HB, Reylland ME, Cusick JK. RELT family members activate p38 and induce apoptosis by a mechanism distinct from TNFR1. Biochem Biophys Res Commun 2017;491:25-32.

27. Lines JL, Sempere LF, Broughton T, Wang L, Noelle R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2014;2:510-7.

28. Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 2014;74:1924-32.

29. Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H, et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother 2018;67:1685-94.

30. Chen L, Zhu YY, Zhang XJ, Wang GL, Li XY, He S, et al. TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma. World J Gastroenterol 2009;15:2270.

31. Chen L, Yuan D, Zhao R, Li H, Zhu J. Suppression of TSPAN1 by RNA interference inhibits proliferation and invasion of colon cancer cells in vitro. Tumori 2010;96:744-50.

32. Chen Y, Meng F, Wang B, He L, Liu Y, Liu Z. Dock2 in the development of inflammation and cancer. Eur J Immunol 2018;48:915-22.

33. Yu J, Wu WK, Li X, He J, Li XX, Ng SS, et al. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut 2015;64:636-45.

34. Liu J, Li H, Sun L, Wang Z, Xing C, Yuan Y. Abruptly methylated-differentially expressed genes and pathways in colorectal cancer. Cancer Cell Int 2017;17:75.

35. Kafetzopoulou LE, Boocock DJ, Dhondalay GKR, Powe DG, Ball GR. Biomarker identification in breast cancer: beta-adrenergic receptor signaling and pathways to therapeutic response. Comput Struct Biotechnol J 2013;6:e201303003.

36. Guo S, Fesler A, Wang H, Ju J. microRNA based prognostic biomarkers in pancreatic Cancer. Biomark Res 2018;6:18.

37. Hou S, Tan J, Yang B, He L, Zhu Y. Effect of alkylglycerol phosphate synthase on the expression profile of circRNAs in the human thyroid cancer cell line FRO. Oncol Lett 2018;15:7889-99.

38. Su H, Lin F, Deng X, Shen L, Fang Y, Fei Z, et al. Profiling and bioinformatics analyses reveal differential circular RNA expression in radioresistant esophageal cancer cells. J Transl Med 2016;14:225.

39. Qiu L, Wang T, Ge Q, Xu H, Wu Y, Tang Q, et al. Circular RNA signature in hepatocellular carcinoma. Cancer 2019;10:3361.

40. Ou M, Lin H, Gong W, Liu F, Chen P, Zhang Y, et al. Comprehensive analysis of circRNA expression patterns in small hepatocellular carcinoma by integrating circRNA and gene expression data. Int J Clin Exp Med 2017;10:2858-65.

41. Li QH, Liu Y, Chen S, Zong ZH, Du YP, Sheng XJ, et al. Circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge. Biomed Pharmacother 2019;114:108832.

42. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res 2012;10:504-15.

43. Afanasyeva EA, Mestdagh P, Kumps C, Vandesompele J, Ehernann V, Theissen J, et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ 2011;18:974.

44. Zhang Z, Yin J, Yang J, Shen W, Zhang C, Mou W, et al. miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/β-catenin signaling pathway. Oncotarget 2016;7:75038.

45. Chen L, Li Y, Fu Y, Peng J, Mo M-H, Stamatakos M, et al. Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One 2013;8:e54213.

46. Jin S, Dui Y, Li C, Fang X, Han H, Wang D. MicroRNA-544 inhibits glioma proliferation, invasion and migration but induces cell apoptosis by targeting PARK7. Am J Transl Res 2016;8:1826.

47. Xiong DD, Dang YW, Lin P, Wen DY, He RQ, Luo DZ, et al. A circRNA–miRNA–mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma. J Transl Med 2018;16:220.

48. Hou BH, Jian ZX, Cui P, Li SJ, Tian RQ, Ou JR. FUS-216a may inhibit pancreatic tumor growth by targeting JAK2. FEBS Lett 2015;589:2224-32.

49. Anaauate AC, Leal MF, Wisnieski F, Santos LC, Gigek CO, Chen ES, et al. Analysis of 8q24. 21 miRNA cluster expression and copy number variation in gastric cancer. Future Med Chem 2019;11:947-58.

50. Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin SE, et al. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res 2008;6:212-21.
Supplementary Figure 1. Boxplots of normalized data.

Supplementary Figure 2. Clustered heatmap for the top 100 differentially expressed mRNAs according to GSE41657. Rows represent circRNAs and columns represent tissue types.

Supplementary Figure 3. Clustered heatmap for the top 100 differentially expressed mRNAs according to GSE128449. Rows represent circRNAs and columns represent tissue types.

Supplementary Figure 4. Clustered heatmap for the top 50 differentially expressed circRNAs according to GSE128449. Rows represent circRNAs and columns represent tissue types.

Supplementary Figure 5. Expression analysis of C10ORF54, TSPAN1 and GAS7 between tumor and normal samples. The boxplots were retrieved from GEPIA based on TCGA data. Tumors and normal samples present in red and gray respectively. Red star indicates significant difference between tumors and adjacent normal tissues (P.value ≤0.01).

| Gene.symbol | Gene.title                                      |
|-------------|------------------------------------------------|
| SBSPON      | somatomedin B and thrombospondin type 1 domain containing |
| ARG2        | arginase 2                                          |
| ACER3       | alkaline ceramidase 3                              |
| TMEM9B      | TMEM9 domain family member B                       |
| RAB3B       | RAB3B, member RAS oncogene family                  |
| FBLN1       | fibrillin 1                                         |
| PLXNC1      | plecin C1                                           |
| IL10RA      | interleukin 10 receptor subunit alpha              |
| AKR1B10     | aldo-keto reductase family 1 member B10            |
| RASSF2      | Ras association domain family member 2             |
| TMEM140     | transmembrane protein 140                          |
| IL1R2       | interleukin 1 receptor type 2                      |
| APOE        | apolipoprotein E                                    |
| NRAP        | nebulin related anchoring protein                   |